On October 12, 2022 Dr. Gregory Fiore, Co-Founder, President and CEO of Exacis Biotherapeutics reported that it will present "Strategies to Develop Safe Cell Therapies Without Compromising Efficacy" at the 3rd Gene and Cell Therapies: CMC, CGT & Vector Manufacturing Summit (Press release, Exacis Biotherapeutics, OCT 12, 2022, View Source [SID1234621925]). Dr. Fiore has gained a deep understanding of the complexity of developing cell-based therapies as CEO. CMO and C-suite advisor of multiple pharmaceutical and biotechnology companies.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Patient safety is essential in developing new therapies," said Dr. Fiore. "Finding the optimal benefit-risk balance where a therapy is as effective as possible, while limiting the risk to patients requires thorough exploration and is crucial for success."

The panel will take place at 5:00 pm CET on Wednesday, November 16, 2022.

The 3rd Gene and Cell Therapies: CMC, CGT & Vector Manufacturing Summit will be November 16-17, in Vienna, Austria and online. The meeting will focus on the unique challenges related to CMC, analytical, process development, automation, manufacturing, facility design, aseptic processing, supply chain and others that developers of gene and cell therapies must resolve.